Results 81 to 90 of about 16,504 (255)

A Clinical Study Shows Safety and Efficacy of Autologous Bone Marrow Mononuclear Cell Therapy to Improve Quality of Life in Muscular Dystrophy Patients

open access: yesCell Transplantation, 2013
Muscular dystrophy is a genetic disorder with no definite cure. A study was carried out on 150 patients diagnosed with muscular dystrophy. These included Duchenne muscular dystrophy, limb-girdle muscular dystrophy, and Becker muscular dystrophy variants.
Alok Sharma M.S., M.Ch.   +7 more
doaj   +1 more source

Prenatal muscle development in a mouse model for the secondary dystroglycanopathies [PDF]

open access: yes, 2016
The defective glycosylation of α-dystroglycan is associated with a group of muscular dystrophies that are collectively referred to as the secondary dystroglycanopathies.
A Leschziner   +49 more
core   +1 more source

The Effect of Anti‐3‐Hydroxy‐3‐Methylglutaryl‐CoA Reductase (HMGCR) Human Autoantibodies on Muscle Regeneration in Mice

open access: yesMuscle &Nerve, Volume 72, Issue 6, Page 1300-1308, December 2025.
ABSTRACT Introduction/Aims Anti‐3‐hydroxy‐3‐methylglutaryl‐CoA reductase (HMGCR) autoantibodies (aAbs) are pathogenic in immune‐mediated necrotizing myopathy (IMNM), partly through complement activation. C5 inhibition did not restore muscle strength in mice or patients with overt IMNM, suggesting additional pathogenic mechanisms.
Sarah Julien   +6 more
wiley   +1 more source

Universal Proteomic Signature After Exercise‐Induced Muscle Injury in Muscular Dystrophies

open access: yesAnnals of Clinical and Translational Neurology
Objective Several neuromuscular disorders (NMDs) are characterized by progressive muscle damage and are marked by the elevation of circulating muscle proteins from activity‐related injury.
Mads G. Stemmerik   +5 more
doaj   +1 more source

Inherited progressive limb-girdle muscular dystrophy type 2A (calpainopathy): a review of literature

open access: yesНервно-мышечные болезни, 2015
The Russian literature gives inadequate attention to the problem of one of the most common form of autosomal recessive progressive limb-girdle muscular dystrophies type 2A (LGMD2A) (calpainopathy). This paper highlights current views on the physiological
D. A. Grishina   +3 more
doaj   +1 more source

Effects of rituximab in two patients with dysferlin-deficient muscular dystrophy [PDF]

open access: yes, 2010
Background. The administration of rituximab (RTX) in vivo results in B-cell depletion, but evidence for multiple mechanisms of action have been reported.
Alberto Lerario   +6 more
core   +3 more sources

A bioinformatic analysis of gene editing off‐target loci altered by common polymorphisms, using ‘PopOff’

open access: yesJournal of the Royal Society of New Zealand, Volume 55, Issue 6, Page 2440-2463, December 2025.
ABSTRACT Gene editing therapies are designed to minimise off‐target editing. However, it is not widespread practice for common polymorphisms to be considered when identifying potential off‐target sites in silico. Nevertheless, genetic variants should be included as they have the potential to alter existing, or to generate new, off‐target sites.
Christopher Samson   +5 more
wiley   +1 more source

Essential neuromuscular advice for pathologists: Limb Girdle Muscular Dystrophy (second of two parts)

open access: yesSurgical and Experimental Pathology
Background Limb Girdle Muscular Dystrophy is defined as a group of progressive autosomal recessive (85%, 28 genes) and autosomal dominant (15%, 5 genes) muscular dystrophies described in at least two unrelated families, affecting individuals that achieve
Ana Cotta   +21 more
doaj   +1 more source

The impact of molecular biology on clinical neurology. [PDF]

open access: yes, 2001
Advances in molecular biology have increased our understanding of both inherited and sporadic forms of neurological disease. In this review, the impact of these advances is discussed in relation to specific neurological conditions.
Ho, SL, Mak, W
core  

Remotely acting SMCHD1 gene regulatory elements: in silico prediction and identification of potential regulatory variants in patients with FSHD [PDF]

open access: yes, 2015
Background: Facioscapulohumeral dystrophy (FSHD) is commonly associated with contraction of the D4Z4 macro-satellite repeat on chromosome 4q35 (FSHD1) or mutations in the SMCHD1 gene (FSHD2).
B Mifsud   +26 more
core   +2 more sources

Home - About - Disclaimer - Privacy